Dataset from A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif®) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

This was a Phase II, randomized, open-label, rater-blinded, three-arm study comparing two
different doses of alemtuzumab (Lemtrada™) and one dose of subcutaneous (SC) interferon
beta-1a (Rebif®) in participants with early, active relapsing-remitting multiple sclerosis
(MS) who had not been previously treated with MS therapies other than steroids. The study was
conducted for an initial period of 3 years and a follow-up to 5 years or more.